XNYS · Drug Manufacturers - General
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$263.96-0.02%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Technical
- Quality & growth
- Sentiment Signal
What to watch
- Valuation
Quality & growth
30%53Moderate
- Revenue growth 10.4%
- EPS growth 68.6%
Valuation
25%30Weak
- P/E 74.3
- EV/Sales 8.3
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
#21 by market cap in our coverage · ~57,000 employees · Listed 2012-12-10 · www.abbvie.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Revenue growth (industry)Top 18%
Gross margin (industry)Top 64%
P/E (industry)Pricier than 80%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
79/100Strong
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 2 sell · 3 neutral of 8 votes
TickerWhale reads ABBV's technical setup as strong at 79/100, not yet ranked against the universe in this run. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+15.0%
- vs 50-day+3.4%
Momentum
Mixed
- RSI (14)59 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rsell
Trend
Mixed
- ADX (14) trend strength14· weak trend
- MACD (12,26,9)buy(histogram 0.453)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 2 sell · 3 neutral.
Result — 3 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)74.3
- P/S (TTM)7.3
- P/B—
- EV/EBITDA—
- EV/Sales8.3
- PEG—
Profitability & returns
- Gross margin71.5%
- Net margin9.8%
- ROE—
- Debt/Equity—
Growth
- Revenue growth (YoY)10.4%
- EPS growth (YoY)68.6%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $467.5B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $61.2B | $56.3B | $54.3B |
| Gross profit | $43.0B | $39.4B | $33.9B |
| Operating income | $15.1B | $9.1B | $12.8B |
| Net income | $4.2B | $4.3B | $4.9B |
| EPS (diluted) | $2.36 | $2.39 | $2.72 |
| Free cash flow | $17.8B | $17.8B | $22.1B |
| Cash | $5.2B | $5.5B | $12.8B |
| Total debt | $67.5B | $67.1B | $59.4B |
| Equity | -$3.3B | $3.3B | $10.4B |
| Net debt | $62.3B | $61.6B | $46.6B |
| Debt / equity | -20.38 | 20.19 | 5.73 |
| Liabilities / assets | 1.02 | 0.98 | 0.92 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBVCurrentAbbvie | — | 79 | 74.3 | — | — | 8.3 | $263.96 | -0.02% | +10.4% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.